Filtered By:
Condition: Heart Valve Disease
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 554 results found since Jan 2013.
Long-term Follow up after Transfemoral Transcatheter Aortic Valve Implantation in Lower Risk Patients Using the Balloon-Expandable Bioprosthesis: Gender-Dependent Outcomes
CONCLUSION: Although considerably more prone to procedural complications, women had a significantly long-term survival benefit after TF-TAVI in lower-risk patients despite similar baseline characteristics.PMID:35486061 | DOI:10.1532/hsf.4451
Source: The Heart Surgery Forum - April 29, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Dritan Useini Markus Schl ömicher Assem Aweimer Peter Haldenwang Justus Strauch Polykarpos Patsalis Source Type: research
Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review
CONCLUSION: Cumulative data analysis reveals that DOAC may provide an effective and safe alternative to VKA in patients with AF after surgically implanted bioprosthetic heart valves or repair with AF. Within a relatively heterogeneous study population, this meta-analysis shows a risk reduction of major bleedings and thromboembolic stroke or systemic embolisms for DOAC.PMID:35481366 | DOI:10.1177/17539447221093963
Source: Adv Data - April 28, 2022 Category: Epidemiology Authors: Stephen Gerfer Ilija Djordjevic Kaveh Eghbalzadeh Navid Mader Thorsten Wahlers Elmar Kuhn Source Type: research
Late-onset cerebral embolism after transcatheter aortic valve implantation under direct oral anticoagulant therapy
We describe the case of a 92-year-old woman with delayed valve thrombosis causing stroke after TAVI, who developed recurrent strokes eight months after TAVI for severe aortic valve stenosis. Transesophageal echocardiography and cardiac computed tomography revealed a string-like thrombus attached to the implanted valve.
Source: Journal of Stroke and Cerebrovascular Diseases - April 28, 2022 Category: Neurology Authors: Shuhei Egashira, Takeshi Yoshimoto, Junpei Koge, Masafumi Ihara Tags: Case Report Source Type: research
Sex-Related Differences in Transcatheter Mitral Valve Repair: A Systematic Review and Meta-Analysis
Conclusion: A trend has emerged in heart valve interventions with males tending to have improved outcomes after surgical intervention and females experiencing equivalent or improved outcomes after transcatheter interventions. This meta-analysis identified increased rates of acute kidney injury for males, increased rates of major bleeding for females, and otherwise comparable morbidity and mortality in males and females undergoing TMVr.
Source: Cardiology - April 20, 2022 Category: Cardiology Source Type: research
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
